Todd J A, Weston T, MacDonald T M, Johnston D A, Dillon J F
Department of Molecular & Cellular Pathology, Ninewells Hospital & Medical School, Dundee, UK.
Aliment Pharmacol Ther. 2001 Feb;15(2):221-6. doi: 10.1046/j.1365-2036.2001.00914.x.
There has been a dramatic rise in incidences of Barrett's oesophagus and oesophageal adenocarcinoma. It has been suggested that the introduction and use of acid suppression therapy may be a factor in the rising incidences of Barrett's oesophagus and oesophageal adenocarcinoma.
This was a record linkage study, using a prescribing database and an endoscopy database. Patients who had undergone their first endoscopy during the period 1992-1995 and received the diagnosis of Barrett's oesophagus or oesophagitis were identified. The prescribing of acid suppressants was compared for the 3 years prior to endoscopy, between those with Barrett's oesophagus and those with oesophagitis.
There was no significant difference between the Barrett's patients and the oesophagitis patients in the proportion that had been exposed to acid suppression therapy (53.4% vs. 51.7%, P=0.704). The mean number of days of prescribing among those who had been exposed to acid suppression therapy was higher in the Barrett's group (340.5 vs. 237.0 days, P=0.001).
Patients with Barrett's oesophagus have received more acid suppressant therapy prior to diagnosis. The reasons for this are not clear. However, 46.6% of Barrett's patients have not been exposed to acid suppressant therapy.
巴雷特食管和食管腺癌的发病率急剧上升。有人认为，抑酸治疗的引入和使用可能是巴雷特食管和食管腺癌发病率上升的一个因素。
这是一项记录链接研究，使用了一个处方数据库和一个内镜检查数据库。确定了在1992年至1995年期间接受首次内镜检查并被诊断为巴雷特食管或食管炎的患者。比较了巴雷特食管患者和食管炎患者在内镜检查前3年的抑酸剂处方情况。
接受抑酸治疗的巴雷特食管患者和食管炎患者比例之间无显著差异（53.4%对51.7%，P = 0.704）。接受抑酸治疗的患者中，巴雷特食管组的平均处方天数更高（340.5天对237.0天，P = 0.001）。
巴雷特食管患者在诊断前接受了更多的抑酸治疗。其原因尚不清楚。然而，46.6%的巴雷特食管患者未接受抑酸治疗。
